FIELD: medicine.
SUBSTANCE: present invention concerns area of medical products, in particular, to a pharmaceutical composition in the form, suitable for introduction in a nose or eyes, containing from 0.0005 to 2% of azelastin hydrochloride in a combination with from 0.5 to 1.5 % of fluticasone or its ester. The invention also concerns a pharmaceutical product containing (i) azelastin hydrochloride and (ii) fluticasone, represented in the form of an aerosolic composition for delivery by means of MDI (a dosing out inhaler), in the form of a insufflation powder or in the form of a nasal spray.
EFFECT: stability improvement, and also maintenance of the improved efficiency of a medical product.
27 cl, 14 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADIN | 2014 |
|
RU2799761C2 |
| TREATMENT OF ALLERGIC RHINITIS USING COMBINATION OF MOMETASONE AND OLOPATADINE | 2014 |
|
RU2686670C2 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2701514C2 |
| PHARMACEUTICAL COMPOSITION, CONTAINING MOMETASONE FUROATE AND AZELASTINE HYDROCHLORIDE, FOR NASAL INTRODUCTION | 2011 |
|
RU2563115C2 |
| TREATMENT OF ALLERGIC RHINITIS IN PEDIATRIC CATEGORY USING A COMBINATION OF MOMETASONE AND OLOPATADINE | 2019 |
|
RU2798030C2 |
| COMPOSITION BASED ON XYLITOL, PREVENTING SEPARATION OF SLIME AND RELATED METHODS AND COMPOSITIONS | 2013 |
|
RU2607892C2 |
| STABLE PHARMACEUTICAL COMPOSITION WITH FIXED DOSE, CONTAINING MOMETASONE AND OLOPATADINE | 2014 |
|
RU2687551C2 |
| COMPOSITION FOR TREATING RHINITIS AND RELATED DISEASES AND METHOD FOR PREPARING IT | 2006 |
|
RU2444351C2 |
| COMBINATION OF LEVOCABASTINE AND FLUTICASONE FUROATE FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC CONDITIONS | 2013 |
|
RU2652352C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ARFORMOTEROL AND FLUTICASONE FUROATE | 2013 |
|
RU2678992C2 |
